Bausch + Lomb Corporation

NYSE:BLCO 株式レポート

時価総額:US$6.9b

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Bausch + Lomb 過去の業績

過去 基準チェック /06

Bausch + Lombの収益は年間平均-74.4%の割合で減少していますが、 Medical Equipment業界の収益は年間 増加しています。収益は年間8.7% 5%割合で 増加しています。

主要情報

-75.8%

収益成長率

-76.3%

EPS成長率

Medical Equipment 業界の成長8.9%
収益成長率5.8%
株主資本利益率-6.7%
ネット・マージン-10.1%
前回の決算情報30 Jun 2024

最近の業績更新

Recent updates

With Buyout Interest, Bausch + Lomb May Still Be Worth Interest At Current Levels

Sep 19

Is Bausch + Lomb (NYSE:BLCO) Using Too Much Debt?

Sep 13
Is Bausch + Lomb (NYSE:BLCO) Using Too Much Debt?

Little Excitement Around Bausch + Lomb Corporation's (NYSE:BLCO) Revenues

Jun 22
Little Excitement Around Bausch + Lomb Corporation's (NYSE:BLCO) Revenues

Bausch + Lomb's Bet-The-Farm Xiidra Acquisition Is Looking Questionable, But Miebo Could Make The Stock A Winner

May 24

Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 32% Below Their Intrinsic Value Estimate

Apr 30
Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 32% Below Their Intrinsic Value Estimate

Is Bausch + Lomb (NYSE:BLCO) Using Too Much Debt?

Mar 25
Is Bausch + Lomb (NYSE:BLCO) Using Too Much Debt?

Many Still Looking Away From Bausch + Lomb Corporation (NYSE:BLCO)

Feb 19
Many Still Looking Away From Bausch + Lomb Corporation (NYSE:BLCO)

Hovering Around 52-Week Low, Bausch + Lomb May Be Poised For A Rebound

Jan 31

Bausch + Lomb Corporation's (NYSE:BLCO) Intrinsic Value Is Potentially 34% Above Its Share Price

Jan 14
Bausch + Lomb Corporation's (NYSE:BLCO) Intrinsic Value Is Potentially 34% Above Its Share Price

Bausch + Lomb: Not A Good Time To Buy (Rating Downgrade)

Nov 08

Why Investors Shouldn't Be Surprised By Bausch + Lomb Corporation's (NYSE:BLCO) Low P/S

Nov 03
Why Investors Shouldn't Be Surprised By Bausch + Lomb Corporation's (NYSE:BLCO) Low P/S

An Intrinsic Calculation For Bausch + Lomb Corporation (NYSE:BLCO) Suggests It's 46% Undervalued

Aug 15
An Intrinsic Calculation For Bausch + Lomb Corporation (NYSE:BLCO) Suggests It's 46% Undervalued

Bausch + Lomb: Growth Should Accelerate As Supply Issues Ease

Aug 09

These Return Metrics Don't Make Bausch + Lomb (NYSE:BLCO) Look Too Strong

May 09
These Return Metrics Don't Make Bausch + Lomb (NYSE:BLCO) Look Too Strong

Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 24% Below Their Intrinsic Value Estimate

Mar 28
Bausch + Lomb Corporation (NYSE:BLCO) Shares Could Be 24% Below Their Intrinsic Value Estimate

Bausch + Lomb Non-GAAP EPS of $0.23 beats by $0.01, revenue of $996M beats by $32.08M

Feb 22

Bausch + Lomb's photodynamic laser gets FDA approval for use with Visudyne

Feb 01

Bausch + Lomb: Still A Favorable Risk-To-Reward Prospect

Jan 24

Bausch + Lomb acquires AcuFocus for cataract lens

Jan 17

収支内訳

Bausch + Lomb の稼ぎ方とお金の使い方。LTMベースの直近の報告された収益に基づく。


収益と収入の歴史

NYSE:BLCO 収益、費用、利益 ( )USD Millions
日付収益収益G+A経費研究開発費
30 Jun 244,495-4561,940328
31 Mar 244,314-3371,822329
31 Dec 234,146-2601,736324
30 Sep 233,969-2071,639322
30 Jun 233,904-1411,612317
31 Mar 233,810-1041,553307
31 Dec 223,76861,478307
30 Sep 223,773581,457299
30 Jun 223,7801361,414285
31 Mar 223,7731751,414281
31 Dec 213,7651821,389271
30 Sep 213,708-781,355267
30 Jun 213,675-531,319265
31 Mar 213,517-441,266257
31 Dec 203,412-181,253253
31 Dec 193,7782981,382258
31 Dec 183,6657101,327221

質の高い収益: BLCOは現在利益が出ていません。

利益率の向上: BLCOは現在利益が出ていません。


フリー・キャッシュフローと収益の比較


過去の収益成長分析

収益動向: BLCOは利益が出ておらず、過去 5 年間で損失は年間74.4%の割合で増加しています。

成長の加速: BLCOの過去 1 年間の収益成長を 5 年間の平均と比較することはできません。現在は利益が出ていないためです。

収益対業界: BLCOは利益が出ていないため、過去 1 年間の収益成長をMedical Equipment業界 ( 2.4% ) と比較することは困難です。


株主資本利益率

高いROE: BLCOは現在利益が出ていないため、自己資本利益率 ( -4.8% ) はマイナスです。


総資産利益率


使用総資本利益率


過去の好業績企業の発掘